{"pmid":32444269,"title":"Immunotherapies for COVID-19: lessons learned from sepsis.","text":["Immunotherapies for COVID-19: lessons learned from sepsis.","Lancet Respir Med","Remy, Kenneth E","Brakenridge, Scott C","Francois, Bruno","Daix, Thomas","Deutschman, Clifford S","Monneret, Guillaume","Jeannet, Robin","Laterre, Pierre-Francois","Hotchkiss, Richard S","Moldawer, Lyle L","32444269"],"journal":"Lancet Respir Med","authors":["Remy, Kenneth E","Brakenridge, Scott C","Francois, Bruno","Daix, Thomas","Deutschman, Clifford S","Monneret, Guillaume","Jeannet, Robin","Laterre, Pierre-Francois","Hotchkiss, Richard S","Moldawer, Lyle L"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32444269","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/S2213-2600(20)30217-4","topics":["Mechanism","Treatment"],"weight":1,"_version_":1667600475774517250,"score":9.490897,"similar":[{"pmid":32393592,"title":"Cytokine storm and the prospects for immunotherapy with COVID-19.","text":["Cytokine storm and the prospects for immunotherapy with COVID-19.","Knowledge about the pathobiology of SARS-COV-2 as it interacts with immune defenses is limited. SARS-COV-2 is spread by droplets that come into contact with mucous membranes. COVID-19 is characterized by 3 stages: asymptomatic-paucisymptomatic incubation, nonsevere symptomatic illness for 80% of those infected, and severe respiratory illness. A syndrome characterized by hypercytokinemic inflammation referred to as a \"cytokine storm\" can occur in patients with advanced disease. Effective antiviral agents that can prevent viral infection in exposed individuals are needed.","Cleve Clin J Med","Calabrese, Leonard H","32393592"],"abstract":["Knowledge about the pathobiology of SARS-COV-2 as it interacts with immune defenses is limited. SARS-COV-2 is spread by droplets that come into contact with mucous membranes. COVID-19 is characterized by 3 stages: asymptomatic-paucisymptomatic incubation, nonsevere symptomatic illness for 80% of those infected, and severe respiratory illness. A syndrome characterized by hypercytokinemic inflammation referred to as a \"cytokine storm\" can occur in patients with advanced disease. Effective antiviral agents that can prevent viral infection in exposed individuals are needed."],"journal":"Cleve Clin J Med","authors":["Calabrese, Leonard H"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393592","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3949/ccjm.87a.ccc008","locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666627827826425856,"score":42.117783},{"pmid":32499129,"title":"Immunotherapies for COVID-19: Restoring the immunity could be the priority.","text":["Immunotherapies for COVID-19: Restoring the immunity could be the priority.","Anaesth Crit Care Pain Med","Allaouchiche, Bernard","32499129"],"journal":"Anaesth Crit Care Pain Med","authors":["Allaouchiche, Bernard"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32499129","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.accpm.2020.05.009","topics":["Mechanism","Treatment"],"weight":1,"_version_":1668804508667346944,"score":42.117783},{"pmid":32490726,"title":"Thromboinflammatory response in SARS-CoV-2 sepsis.","text":["Thromboinflammatory response in SARS-CoV-2 sepsis.","Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought.","Med Leg J","Maiese, Aniello","Passaro, Giovanna","Matteis, Alessandra DE","Fazio, Valentina","Raffaele, La Russa","Paolo, Marco Di","32490726"],"abstract":["Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought."],"journal":"Med Leg J","authors":["Maiese, Aniello","Passaro, Giovanna","Matteis, Alessandra DE","Fazio, Valentina","Raffaele, La Russa","Paolo, Marco Di"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32490726","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1177/0025817220926915","keywords":["sars-cov-2","sepsis, covid-19, thrombosis, coagulopathy"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668623433562324992,"score":41.407707},{"pmid":32468851,"title":"Facing SARS-CoV-2 outbreak in immunotherapy era.","text":["Facing SARS-CoV-2 outbreak in immunotherapy era.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread represents a sanitary emergency all over the world. Viral biology is only partially known with some aspects in common with other CoV and the damage observed in most severe cases is due to intense inflammation. Immunotherapy restores immunological activity against cancer cells and it has become a standard treatment for several cancers. We carried out an examination of available data concerning with the effects exerted by both SARS-CoV-2 and the most widespread immunotherapy treatments on the immune system in order to hypothesize mechanisms underlying potential and mutual interaction. We provided an analysis of laboratory, clinical and therapeutic data related with severe acute respiratory syndrome coronavirus. We finally focused on implications of immunotherapy treatments in clinical practice.","Future Oncol","Citarella, Fabrizio","Russano, Marco","Pantano, Francesco","Dell'Aquila, Emanuela","Vincenzi, Bruno","Tonini, Giuseppe","Santini, Daniele","32468851"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread represents a sanitary emergency all over the world. Viral biology is only partially known with some aspects in common with other CoV and the damage observed in most severe cases is due to intense inflammation. Immunotherapy restores immunological activity against cancer cells and it has become a standard treatment for several cancers. We carried out an examination of available data concerning with the effects exerted by both SARS-CoV-2 and the most widespread immunotherapy treatments on the immune system in order to hypothesize mechanisms underlying potential and mutual interaction. We provided an analysis of laboratory, clinical and therapeutic data related with severe acute respiratory syndrome coronavirus. We finally focused on implications of immunotherapy treatments in clinical practice."],"journal":"Future Oncol","authors":["Citarella, Fabrizio","Russano, Marco","Pantano, Francesco","Dell'Aquila, Emanuela","Vincenzi, Bruno","Tonini, Giuseppe","Santini, Daniele"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468851","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.2217/fon-2020-0340","keywords":["covid-19","sars-cov-2","immune checkpoint inhibitors","immunotherapy","inflammation"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167109868257280,"score":40.695534}]}